EBG Biosimilars 2015

EGA: Low patient recruitment sends biosimilar trials to Eastern Europe

By Fiona BARRY

- Last updated on GMT

Joerg Windisch speaking at the EGA-EBG Conference in Tower Hill, London. (Image: EGA)
Joerg Windisch speaking at the EGA-EBG Conference in Tower Hill, London. (Image: EGA)

Related tags Europe Eastern europe

Reluctant doctors and varying reimbursement policies are affecting biosimilar trial recruitment, experts said at the European Generics Association’s biosimilars conference in London last week.

Sponsor companies are moving trials to Eastern Europe to try to find study participants, investment analyst Ronny Gal of Sanford Bernstein, told an audience at the 13th​ EGA-European Biosimilars Group Conference on Thursday.

Some of the players who are trying to get into the market first are pushing for trials in Belarus, Ukraine, Hungary, Poland.

The idea is to have a few centres, where you have very tight control over what a centre does, minimise variability, and recruit a lot of patients for those trials.​”

But Gal said a strategy of concentrating trials is one region could bring its own problems.

I wonder if at any point will the others begin to argue that a trial with primarily Eastern European population will be non-representative.”

Other companies are beginning to cast their net wider with a “brute recruiting approach​”, spreading a few centres across several different countries, bringing greater genetic variability, he said.

Educating doctors

However biosimilar makers decide to solve the recruitment process, Gal was clear it is currently a problem of “extreme difficulty​” and a “fly in the ointment​” for gene therapy.

Persuading physicians in the UK, France and Scandinavia to participate is a particular hurdle.

Doctors do not see the benefit of their patients being on those trials, although there are clearly system benefits. And most of those trials go elsewhere.”

This view was seconded at the conference by Joerg Windisch, Chair of the European Biosimilars Group (EBG, part of EGA) and Sandoz Chief Science Officer.

Windisch said the answer lies in assuring doctors – who prize clinical data over other kinds – of the safety and efficacy of biosimilars compared to originator biologics.

If you look at the evidence that leads to approval of a biosimilar, you’re connecting the biosimilar to the clinical data and experience of the original product.

“The most sensitive way of doing that is with all the state of the art functional and analytic data you have available. But that’s typically not what clinicians understand by the word ‘data’. So that’s where the education comes in.”

Windisch said approvals of the first generation of oncology biosimilars will help persuade doctors in other specialties “and then the dam will break and it will get easier. Pioneering work means clearing the brush.​”

He stressed the difficulty of convincing doctors and patients to try a biosimilar in countries where the costs of originator biopharmaceuticals are reimbursed.

There you have to work with physicians who understand the long-term effect biosimilars will have regarding long-term access and sustainability of healthcare systems.

It may seem naïve, we actually thought so a few years ago, but you can actually find these people. If you collaborate with them, they have a network of other people; it’s contagious.”

Willingness to go into biosimilar trials is higher in countries where access to reference products is lower and more expensive, he said.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more